MXPA06007511A - Drug granule coatings that impart smear resistance during mechanical compression. - Google Patents

Drug granule coatings that impart smear resistance during mechanical compression.

Info

Publication number
MXPA06007511A
MXPA06007511A MXPA06007511A MXPA06007511A MXPA06007511A MX PA06007511 A MXPA06007511 A MX PA06007511A MX PA06007511 A MXPA06007511 A MX PA06007511A MX PA06007511 A MXPA06007511 A MX PA06007511A MX PA06007511 A MXPA06007511 A MX PA06007511A
Authority
MX
Mexico
Prior art keywords
disclosed
substrate
mechanical compression
coating
granule
Prior art date
Application number
MXPA06007511A
Other languages
Spanish (es)
Inventor
Noymi Yam
David Edgren
Alya Khan
Abdul Majid Qureshi
James Ergun
Satishkumar Ramachandran
Original Assignee
Johnson & Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson filed Critical Johnson & Johnson
Publication of MXPA06007511A publication Critical patent/MXPA06007511A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Abstract

A drug formulation is disclosed comprising granules having a substrate and a coating, said granule substrate comprising a solubilizing surfactant or a low solubility therapeutic drug, or both, and said granule coating comprising a hydrophilic polymer. Also disclosed is a drug formulation consisting of a tablet core made by mechanical compression, wherein said tablet core comprises granules having a substrate and a coating, said granule substrate comprising a solubilizing surfactant or a low solubility therapeutic drug, or both, and said granule coating comprising a hydrophilic polymer. Also disclosed is a dosage form for oral administration of topiramate, comprising a tablet core and an osmotic delivery system. Methods for controlling topiramate release patterns by altering the composition of the topiramate dosage form are also disclosed.
MXPA06007511A 2003-12-29 2004-12-28 Drug granule coatings that impart smear resistance during mechanical compression. MXPA06007511A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53347003P 2003-12-29 2003-12-29
US53311203P 2003-12-29 2003-12-29
PCT/US2004/043931 WO2005065647A2 (en) 2003-12-29 2004-12-28 Drug granule coatings that impart smear resistance during mechanical compression

Publications (1)

Publication Number Publication Date
MXPA06007511A true MXPA06007511A (en) 2009-06-10

Family

ID=34752987

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06007511A MXPA06007511A (en) 2003-12-29 2004-12-28 Drug granule coatings that impart smear resistance during mechanical compression.

Country Status (6)

Country Link
EP (1) EP1701707A2 (en)
JP (1) JP2007517062A (en)
AU (1) AU2004312083A1 (en)
CA (1) CA2551825A1 (en)
MX (1) MXPA06007511A (en)
WO (1) WO2005065647A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007169273A (en) * 2005-11-28 2007-07-05 Takeda Chem Ind Ltd Medicinal preparation of which attachment to pestle is improved
JP5527921B2 (en) * 2006-12-22 2014-06-25 エスエス製薬株式会社 Oral solid composition concealing bitterness
DE102012014848A1 (en) * 2012-07-27 2012-10-31 Heilerde-Gesellschaft Luvos Just GmbH & Co. KG Healing clay-composition present as non-coated or as coated granules, comprises healing clay and binding agent containing at least one water soluble polymer e.g. starch, tragacanth or cellulose acetate, cellulose ether
JP6466399B2 (en) 2013-03-15 2019-02-06 アプレシア・ファーマスーティカルズ・カンパニー Topiramate rapidly dispersible dosage form
US20220211688A1 (en) 2019-04-25 2022-07-07 Fuji Pharma Co., Ltd. Pharmaceutical preparation and method for producing the same
TW202216142A (en) 2020-10-28 2022-05-01 日商基諾製藥股份有限公司 Pharmaceutical composition for preventing or treating viral perivaginal disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA65607C2 (en) * 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Pharmaceutical composition (variants) and process for its preparation
AU2003225102A1 (en) * 2002-04-23 2003-11-10 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
AR039744A1 (en) * 2002-06-26 2005-03-09 Alza Corp METHODS AND DOSAGE FORMS TO INCREASE THE SOLUBILITY OF PHARMACOS COMPOSITIONS FOR CONTROLLED ADMINISTRATION
WO2004010970A1 (en) * 2002-07-29 2004-02-05 Alza Corporation Formulations and dosage forms for controlled delivery of topiramate
AU2004264316A1 (en) * 2003-08-06 2005-02-24 Alza Corporation Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
EP1701697A2 (en) * 2003-09-02 2006-09-20 ALZA Corporation Novel drug compositions and dosage forms of topiramate
US20050169992A1 (en) * 2003-12-23 2005-08-04 Frank Jao Methods and dosage forms for increasing solubility of drug compositions for controlled delivery

Also Published As

Publication number Publication date
WO2005065647A3 (en) 2005-12-08
CA2551825A1 (en) 2005-07-21
EP1701707A2 (en) 2006-09-20
JP2007517062A (en) 2007-06-28
WO2005065647A2 (en) 2005-07-21
AU2004312083A1 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
WO2007054976A3 (en) Lipid based controlled release pharmaceutical composition
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
CA2446712C (en) System for osmotic delivery of pharmaceutically active agents
US20070092573A1 (en) Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
MXPA03012041A (en) Gastric retention controlled drug delivery system.
WO2002053100A3 (en) Pharmaceutical dosage form for oral administration of low molecular weight heparin
HRP20100372T1 (en) Pharmaceutical compositions of a neuroactive steroid and uses thereof
BR0103033A (en) Pharmaceutical particles of masked flavor
KR20130086128A (en) Easily dosable solid preparation
WO2005117843A3 (en) Sustained release preparations
WO2005009357A3 (en) Controlled release compositions
HK1087031A1 (en) Subcutaneous implants having limited initial release of the active principle and subsequent linearlyvarying extended release thereof
EP1460998B1 (en) Extended release pharmaceutical tablet of metformin
AU2001291526A1 (en) Sustained release composition containing clarithromycin
BG108516A (en) Pharmaceutical formulation
WO2006053089A3 (en) Methods and formulations for making pharmaceutical compositions containing bupropion
WO2003074033A8 (en) Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
WO2005007074A3 (en) Gellan gum based oral controlled release dosage forms- a novel platform technology for gastric retention
MXPA06007511A (en) Drug granule coatings that impart smear resistance during mechanical compression.
CA2417887A1 (en) Particulate composition of eletriptan
WO2004078111A3 (en) Extended release minocycline compositions and processes for their preparation
WO2005013935A3 (en) Composition for releasing a weak base for an extended period of time
WO2007144902A8 (en) Chewable bilayer tablet formulation
WO2003096874A3 (en) Coated sustained release tablets of a hygroscopic compound for once-a-day therapy
KR100920856B1 (en) Extended-release preparation containing selective serotonin reuptake inhibitor and process for the preparation thereof